Anti-Fibrinolytic Drugs - Switzerland

The Anti-Fibrinolytic Drugs market in Switzerland is forecasted to witness a significant increase in revenue, with projected earnings of US$110.00m by the year 2024.
The market is expected to exhibit a steady annual growth rate of 4.65% (CAGR 2024-2029), leading to a market volume of US$138.10m by 2029.
In comparison to other countries globally, United States will generate the highest revenue in the market, amounting to US$9.86bn in 2024.
Switzerland's pharmaceutical industry continues to lead in the development and production of cutting-edge anti-fibrinolytic drugs, ensuring high-quality treatment for patients.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Switzerland, a country known for its scenic beauty, is also a hub of pharmaceutical and biotech industries. The Anti-Fibrinolytic Drugs market in Switzerland has been growing at a steady pace in the past few years.

Customer preferences: Switzerland is one of the countries with a high incidence of bleeding disorders, leading to an increasing demand for Anti-Fibrinolytic Drugs. The aging population and the high prevalence of cardiovascular diseases in the country are the primary drivers of the market. Patients with hemophilia, liver disease, and other bleeding disorders require Anti-Fibrinolytic Drugs to prevent excessive bleeding during surgery or trauma.

Trends in the market: The Anti-Fibrinolytic Drugs market in Switzerland is witnessing a shift towards personalized medicine. The development of gene therapies and the use of biomarkers for diagnosis and treatment are some of the trends that are gaining traction in the market. The market is also witnessing an increase in the use of non-invasive procedures for the diagnosis of bleeding disorders.

Local special circumstances: Switzerland is home to some of the world's leading pharmaceutical and biotech companies, which are actively involved in the development of Anti-Fibrinolytic Drugs. The country has a well-established healthcare system, which ensures that patients have access to the latest treatments and therapies. The Swiss government has also been promoting the use of innovative therapies and technologies in the healthcare sector.

Underlying macroeconomic factors: The Swiss economy is one of the most stable and prosperous in the world. The country has a high standard of living, and its citizens have access to quality healthcare services. The pharmaceutical and biotech industries are major contributors to the Swiss economy, and the government has been actively promoting these industries. The country's favorable business environment and strong intellectual property laws have attracted many multinational companies to set up their operations in Switzerland.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.